The National Comprehensive Cancer Network (NCCN) has updated its ovarian cancer guidelines version 3.2025 to recommend niraparib as maintenance therapy for patients with BRCA wild-type or homologous recombination (HR)–deficiency who did not receive bevacizumab during primary treatment.